Navigation Links
Xanodyne Announces New President/CEO and Completes $38 Million Equity Financing
Date:6/4/2009

NEWPORT, Ky., June 4 /PRNewswire/ -- Xanodyne Pharmaceuticals, Inc. is pleased to announce that Michael J. Valentino has been named to the position of President and Chief Executive Officer and continues as a member of the Company's Board of Directors. In addition to Mr. Valentino's announcement, Xanodyne completed an equity financing of $38 million led by MPM Capital. Current investors' participation also included; AIG Investments' sponsored funds, Aisling Capital, Blue Chip Venture Company, Essex Woodlands Health Ventures, HealthCare Ventures, LLC, and Union Springs.

Mr. Valentino most recently served as President and CEO, Adams Respiratory Therapeutics (Nasdaq: ARXT) and has over 30 years of experience in the healthcare industry, including a broad range of critical leadership positions at major pharmaceutical companies including Alpharma, Novartis AG, Pharmacia/Upjohn and Warner Lambert. Mr. Valentino successfully transformed Adams into a fully integrated specialty pharmaceutical company. In addition, under his leadership Adams completed its initial public offering in July 2005, which was ranked by The Wall Street Journal as the No. 1 Health Care IPO in 2005. In January 2008, he successfully led the sale of the company to Reckitt Benckiser for $2.3B.

Mr. Valentino said, "I look forward to working closely with the Xanodyne management team to bring two exciting pipeline assets to the US marketplace within the next 12-18 months. Our efforts will be focused on aggressively executing our commercialization plans for Zipsor(TM) (diclofenac potassium - acute pain) and XP12B (tranexamic acid - heavy menstrual bleeding). The closing of our financing demonstrates the continued commitment of our investor group to complete the NDA process and execute the launch plans for these two important new products."

Rolf Classon, Chairman of the Board said, "The Board is excited about the achievement of these important milestones for Xanodyne. Mike brings major pharmaceutical and commercial experience to the team while the financing brings the critical resources needed for the launches. Xanodyne is now in a position to expand its current commercial product portfolio with an emerging pipeline to generate near term growth."

About Xanodyne

Xanodyne Pharmaceuticals, Inc., which commenced operations in 2001, is an integrated specialty pharmaceutical company with both development and commercial capabilities focused on women's healthcare and pain management. Xanodyne markets a portfolio of revenue generating products consisting of FDA approved pharmaceuticals and a line of prenatal vitamins. Additionally, Xanodyne is advancing a late stage pipeline of product candidates targeted at significant potential markets in Xanodyne's focus areas.


'/>"/>
SOURCE Xanodyne Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Xanodynes New Drug Application for the Treatment of Heavy Menstrual Bleeding (Menorrhagia) Accepted for Filing with a Priority Review Classification
2. US Oncology, Inc. Announces $465 Million Senior Secured Notes Offering
3. DATATRAK Announces Receipt of NASDAQ Panel Decision to Delist Common Shares
4. CorVel Announces Revenues and Earnings
5. Conceptual Options, a Center for Surrogacy & Egg Donation, Announces Third Party Assurance Program
6. Orlando Dermatology Aesthetic & Clinical (ODAC) Conference Announces Its 2010 Event
7. Synthetech Announces Fiscal 2009 Results
8. Martek Announces Second Quarter 2009 Financial Results
9. Medi-Share Program Announces New Healthcare Program Offerings for Christian Community
10. Ambry Genetics Announces Launch of Chromosomal Microarray to Offer Whole Genome Analysis
11. One Woman Initiative Announces First Grants to Womens Organizations in Five Nations
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/9/2016)... ... December 09, 2016 , ... "I have gout, and I wanted ... family recipe, which is meant to relieve gout and pain caused by varicose veins. ... energy boost every time. It relieved what VA doctors called the worst sinusitis case ...
(Date:12/9/2016)... ... December 09, 2016 , ... The ... Hotel in New York, NY, on December 3rd, to benefit Holy Name Medical ... the annual event, which raised over $1 million - the largest event in ...
(Date:12/8/2016)... ... December 08, 2016 , ... The Florida Hospital ... and Hyperbaric Medical Society (UHMS), the leading authority in hyperbaric medicine. This accreditation ... a few hospitals and facilities have earned this distinction. This is the second ...
(Date:12/8/2016)... ... December 08, 2016 , ... Mirixa Corporation , ... and other pharmacist-delivered patient care services, has announced the promotions of Karen Litsinger ... vice president of sales. , Litsinger joined Mirixa in 2008 after serving ...
(Date:12/8/2016)... ... December 08, 2016 , ... SunView Software aims to ... that are both engaging and easy to use. Coming off the heels of ... revealed today its plans to roll out new AI-powered self-service enhancements to help ...
Breaking Medicine News(10 mins):
(Date:12/9/2016)... 9, 2016 Research and Markets has ... Forecast to 2021" report to their offering. ... Market growth ... models in the pharmaceutical and biotechnology industry and technological advancements ... funding. Emerging markets and growing research activities in toxicology and ...
(Date:12/9/2016)... -- RxWiki Inc., a digital health company that powers the ... of pharmacies through its Digital Pharmacist SaaS platform, today ... on Fire" Award in the Health and Life Sciences ... award as one of Austin,s fastest growing companies," said ... "Our platform gives independent retail pharmacies the digital tools ...
(Date:12/9/2016)... SAN DIEGO , Dec. 9, 2016 /PRNewswire/ ... with Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX, ... program targeting ,LpxC, for the treatment of bacterial ... LpxC has been recognized as an attractive antibacterial ... however, a lack of suitable chemical starting points ...
Breaking Medicine Technology: